Pyrimidine metabolism, Nucleoside diphosphate kinase Uncharacterized
| Source | Evidence on protein | Close homologs | 
|---|---|---|
| Cuervo et al. | no | yes: 0 | 
| Hassani et al. | no | yes: 0 | 
| Forrest at al. (metacyclic) | no | yes: 0 | 
| Forrest at al. (procyclic) | no | yes: 0 | 
| Silverman et al. | no | yes: 0 | 
| Pissara et al. | no | yes: 0 | 
| Source | Evidence on protein | Close homologs | 
|---|---|---|
| Pires et al. | no | yes: 0 | 
| Source | Evidence on protein | Close homologs | 
|---|---|---|
| Silverman et al. | no | yes: 0 | 
| Source | Evidence on protein | Close homologs | 
|---|---|---|
| Jamdhade et al. | no | yes: 0 | 
| Source | Evidence on protein | Close homologs | 
|---|---|---|
| DeepLoc | ||
| SignalP6 | no | yes: 0, no: 21 | 
| NetGPI | no | yes: 0, no: 21 | 
| Term | Name | Level | Count | 
|---|---|---|---|
| GO:0005813 | centrosome | 3 | 2 | 
| GO:0005815 | microtubule organizing center | 2 | 2 | 
| GO:0005929 | cilium | 4 | 1 | 
| GO:0005930 | axoneme | 2 | 2 | 
| GO:0042995 | cell projection | 2 | 1 | 
| GO:0043226 | organelle | 2 | 1 | 
| GO:0043227 | membrane-bounded organelle | 3 | 1 | 
| GO:0110165 | cellular anatomical entity | 1 | 2 | 
| GO:0120025 | plasma membrane bounded cell projection | 3 | 1 | 
Related structures:
AlphaFold database: A4IA74
| Term | Name | Level | Count | 
|---|---|---|---|
| GO:0006793 | phosphorus metabolic process | 3 | 16 | 
| GO:0006796 | phosphate-containing compound metabolic process | 4 | 16 | 
| GO:0008152 | metabolic process | 1 | 16 | 
| GO:0009987 | cellular process | 1 | 16 | 
| GO:0016310 | phosphorylation | 5 | 16 | 
| GO:0044237 | cellular metabolic process | 2 | 16 | 
| Term | Name | Level | Count | 
|---|---|---|---|
| GO:0003824 | catalytic activity | 1 | 16 | 
| GO:0016301 | kinase activity | 4 | 16 | 
| GO:0016740 | transferase activity | 2 | 16 | 
| GO:0016772 | transferase activity, transferring phosphorus-containing groups | 3 | 16 | 
| GO:0004550 | nucleoside diphosphate kinase activity | 5 | 9 | 
| GO:0016776 | phosphotransferase activity, phosphate group as acceptor | 4 | 9 | 
| GO:0019205 | nucleobase-containing compound kinase activity | 5 | 9 | 
| Leishmania | From | To | Domain/Motif | Score | 
|---|---|---|---|---|
| CLV_C14_Caspase3-7 | 176 | 180 | PF00656 | 0.463 | 
| CLV_NRD_NRD_1 | 156 | 158 | PF00675 | 0.508 | 
| CLV_PCSK_KEX2_1 | 51 | 53 | PF00082 | 0.357 | 
| CLV_PCSK_PC1ET2_1 | 51 | 53 | PF00082 | 0.377 | 
| CLV_PCSK_PC7_1 | 47 | 53 | PF00082 | 0.396 | 
| CLV_PCSK_SKI1_1 | 256 | 260 | PF00082 | 0.213 | 
| CLV_PCSK_SKI1_1 | 338 | 342 | PF00082 | 0.305 | 
| CLV_PCSK_SKI1_1 | 9 | 13 | PF00082 | 0.325 | 
| DEG_APCC_DBOX_1 | 255 | 263 | PF00400 | 0.507 | 
| DOC_MAPK_gen_1 | 51 | 57 | PF00069 | 0.312 | 
| DOC_MAPK_RevD_3 | 38 | 52 | PF00069 | 0.479 | 
| DOC_PP4_FxxP_1 | 139 | 142 | PF00568 | 0.308 | 
| DOC_PP4_FxxP_1 | 251 | 254 | PF00568 | 0.440 | 
| DOC_USP7_MATH_1 | 204 | 208 | PF00917 | 0.317 | 
| DOC_USP7_MATH_1 | 90 | 94 | PF00917 | 0.395 | 
| DOC_USP7_UBL2_3 | 159 | 163 | PF12436 | 0.284 | 
| DOC_USP7_UBL2_3 | 305 | 309 | PF12436 | 0.523 | 
| LIG_Actin_WH2_2 | 36 | 53 | PF00022 | 0.419 | 
| LIG_BIR_II_1 | 1 | 5 | PF00653 | 0.519 | 
| LIG_FHA_1 | 1 | 7 | PF00498 | 0.660 | 
| LIG_FHA_1 | 146 | 152 | PF00498 | 0.334 | 
| LIG_FHA_1 | 270 | 276 | PF00498 | 0.438 | 
| LIG_FHA_1 | 282 | 288 | PF00498 | 0.451 | 
| LIG_FHA_1 | 35 | 41 | PF00498 | 0.396 | 
| LIG_FHA_1 | 65 | 71 | PF00498 | 0.365 | 
| LIG_FHA_1 | 83 | 89 | PF00498 | 0.295 | 
| LIG_FHA_1 | 94 | 100 | PF00498 | 0.318 | 
| LIG_FHA_2 | 120 | 126 | PF00498 | 0.376 | 
| LIG_FHA_2 | 174 | 180 | PF00498 | 0.455 | 
| LIG_LIR_Apic_2 | 137 | 142 | PF02991 | 0.432 | 
| LIG_LIR_Apic_2 | 250 | 254 | PF02991 | 0.442 | 
| LIG_LIR_Gen_1 | 162 | 171 | PF02991 | 0.444 | 
| LIG_LIR_Gen_1 | 223 | 233 | PF02991 | 0.372 | 
| LIG_LIR_Nem_3 | 102 | 108 | PF02991 | 0.388 | 
| LIG_LIR_Nem_3 | 162 | 168 | PF02991 | 0.437 | 
| LIG_LIR_Nem_3 | 223 | 228 | PF02991 | 0.372 | 
| LIG_LIR_Nem_3 | 253 | 258 | PF02991 | 0.454 | 
| LIG_MYND_3 | 259 | 263 | PF01753 | 0.413 | 
| LIG_SH2_CRK | 255 | 259 | PF00017 | 0.434 | 
| LIG_SH2_CRK | 298 | 302 | PF00017 | 0.523 | 
| LIG_SH2_STAP1 | 298 | 302 | PF00017 | 0.523 | 
| LIG_SH2_STAP1 | 336 | 340 | PF00017 | 0.434 | 
| LIG_SH2_STAT5 | 111 | 114 | PF00017 | 0.335 | 
| LIG_SH2_STAT5 | 31 | 34 | PF00017 | 0.382 | 
| LIG_SH2_STAT5 | 336 | 339 | PF00017 | 0.452 | 
| LIG_SH2_STAT5 | 49 | 52 | PF00017 | 0.312 | 
| LIG_SH3_3 | 16 | 22 | PF00018 | 0.549 | 
| LIG_SH3_3 | 207 | 213 | PF00018 | 0.428 | 
| LIG_SH3_3 | 52 | 58 | PF00018 | 0.341 | 
| LIG_SUMO_SIM_anti_2 | 206 | 212 | PF11976 | 0.435 | 
| LIG_SUMO_SIM_anti_2 | 282 | 290 | PF11976 | 0.427 | 
| LIG_SUMO_SIM_anti_2 | 37 | 42 | PF11976 | 0.461 | 
| LIG_SUMO_SIM_par_1 | 150 | 156 | PF11976 | 0.443 | 
| LIG_SUMO_SIM_par_1 | 282 | 290 | PF11976 | 0.456 | 
| LIG_SUMO_SIM_par_1 | 34 | 42 | PF11976 | 0.456 | 
| MOD_CK1_1 | 60 | 66 | PF00069 | 0.357 | 
| MOD_CK1_1 | 93 | 99 | PF00069 | 0.353 | 
| MOD_CK2_1 | 121 | 127 | PF00069 | 0.425 | 
| MOD_CK2_1 | 277 | 283 | PF00069 | 0.492 | 
| MOD_CK2_1 | 315 | 321 | PF00069 | 0.477 | 
| MOD_GlcNHglycan | 136 | 139 | PF01048 | 0.452 | 
| MOD_GlcNHglycan | 216 | 219 | PF01048 | 0.291 | 
| MOD_GlcNHglycan | 222 | 225 | PF01048 | 0.284 | 
| MOD_GlcNHglycan | 244 | 247 | PF01048 | 0.273 | 
| MOD_GlcNHglycan | 34 | 37 | PF01048 | 0.419 | 
| MOD_GlcNHglycan | 44 | 47 | PF01048 | 0.465 | 
| MOD_GlcNHglycan | 59 | 62 | PF01048 | 0.348 | 
| MOD_GSK3_1 | 169 | 176 | PF00069 | 0.391 | 
| MOD_GSK3_1 | 233 | 240 | PF00069 | 0.486 | 
| MOD_GSK3_1 | 265 | 272 | PF00069 | 0.496 | 
| MOD_GSK3_1 | 277 | 284 | PF00069 | 0.433 | 
| MOD_GSK3_1 | 60 | 67 | PF00069 | 0.396 | 
| MOD_N-GLC_1 | 204 | 209 | PF02516 | 0.293 | 
| MOD_N-GLC_2 | 293 | 295 | PF02516 | 0.176 | 
| MOD_NEK2_1 | 1 | 6 | PF00069 | 0.511 | 
| MOD_NEK2_1 | 145 | 150 | PF00069 | 0.349 | 
| MOD_NEK2_1 | 262 | 267 | PF00069 | 0.454 | 
| MOD_NEK2_1 | 269 | 274 | PF00069 | 0.438 | 
| MOD_NEK2_1 | 32 | 37 | PF00069 | 0.506 | 
| MOD_NEK2_1 | 50 | 55 | PF00069 | 0.358 | 
| MOD_PKA_2 | 169 | 175 | PF00069 | 0.406 | 
| MOD_Plk_1 | 204 | 210 | PF00069 | 0.278 | 
| MOD_Plk_1 | 281 | 287 | PF00069 | 0.450 | 
| MOD_Plk_1 | 93 | 99 | PF00069 | 0.356 | 
| MOD_Plk_2-3 | 34 | 40 | PF00069 | 0.361 | 
| MOD_Plk_4 | 204 | 210 | PF00069 | 0.278 | 
| MOD_Plk_4 | 265 | 271 | PF00069 | 0.496 | 
| MOD_Plk_4 | 297 | 303 | PF00069 | 0.506 | 
| MOD_Plk_4 | 64 | 70 | PF00069 | 0.339 | 
| TRG_DiLeu_BaEn_3 | 102 | 108 | PF01217 | 0.254 | 
| TRG_ENDOCYTIC_2 | 111 | 114 | PF00928 | 0.347 | 
| TRG_ENDOCYTIC_2 | 255 | 258 | PF00928 | 0.428 | 
| TRG_ENDOCYTIC_2 | 298 | 301 | PF00928 | 0.523 | 
| TRG_ENDOCYTIC_2 | 336 | 339 | PF00928 | 0.447 | 
| TRG_NES_CRM1_1 | 277 | 289 | PF08389 | 0.470 | 
| TRG_NLS_MonoExtC_3 | 156 | 162 | PF00514 | 0.291 | 
| TRG_Pf-PMV_PEXEL_1 | 86 | 91 | PF00026 | 0.403 | 
| Protein | Taxonomy | Sequence identity | Coverage | 
|---|---|---|---|
| A0A0N1IJQ8 | Leptomonas seymouri | 72% | 100% | 
| A0A0N1PC23 | Leptomonas seymouri | 27% | 100% | 
| A0A0S4IXH2 | Bodo saltans | 28% | 100% | 
| A0A1X0P5C0 | Trypanosomatidae | 30% | 100% | 
| A0A1X0PAT4 | Trypanosomatidae | 46% | 98% | 
| A0A3Q8IJQ8 | Leishmania donovani | 28% | 100% | 
| A0A3R7M6K1 | Trypanosoma rangeli | 46% | 99% | 
| A0A3R7N390 | Trypanosoma rangeli | 30% | 100% | 
| A0A3S7X855 | Leishmania donovani | 99% | 100% | 
| A4HB17 | Leishmania braziliensis | 84% | 100% | 
| A4HN58 | Leishmania braziliensis | 28% | 100% | 
| A4IBS5 | Leishmania infantum | 28% | 100% | 
| C9ZM33 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 45% | 98% | 
| C9ZYU7 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 30% | 100% | 
| E9AFL1 | Leishmania major | 28% | 100% | 
| E9B587 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 94% | 100% | 
| E9B6R5 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 28% | 100% | 
| Q4Q2P6 | Leishmania major | 94% | 100% | 
| Q5E9Y9 | Bos taurus | 25% | 91% | 
| Q9QXL7 | Rattus norvegicus | 25% | 87% | 
| Q9QXL8 | Mus musculus | 24% | 87% | 
| Q9Y5B8 | Homo sapiens | 24% | 91% | 
| V5BXY9 | Trypanosoma cruzi | 28% | 99% | 
| V5DLW4 | Trypanosoma cruzi | 45% | 98% |